Circulating Tumor DNA Clinical Trial
Official title:
Clinical Sensitivity Verification Study of Circulating Tumor Cells Gene Mutation Detection From Advanced NSCLC Patients
Verify the Coincidence rate between Circulating tumor cells (CTCs) and tumor tissue or Circulating tumor DNA (ctDNA) of advanced NSCLC patients with Driver gene mutation
1. Enrich CTCs from advanced Non-Small Cell Lung Cancer (NSCLC) patients with Driver gene
mutation, and detect the Epidermal Growth Factor Receptor (EGFR) mutation, Anaplastic
lymphoma kinase (ALK) fusion, ROS proto-oncogene receptor tyrosine kinase 1 (ROS1)
fusion, RET proto-oncogene (RET) fusion and Mesenchymal-Epithelial Transition factor
(MET) 14 exon skipping by Lung cancer Polymerase Chain Reaction (PCR) panel kit, and
verify the mutation coincidence rate between CTCs and tumor tissue.
2. Enrich ctDNA from advanced NSCLC patients with Driver gene mutation, detect the EGFR
mutation by PCR, and detect the ALK fusion, ROS1 fusion, RET fusion and MET 14 exon
skipping by next generation sequencing (NGS), and compare the mutation coincidence rate
between CTCs and ctDNA.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05167604 -
Clinical Value of MRD Monitoring for Adjuvant Therapy in Postoperative NSCLC
|
||
Recruiting |
NCT05598528 -
Exploring the Mechanism of Primary Resistance to Third-generation EGFR-TKIs as First-line Treatment in EGFR-positive Advanced NSCLC (PRECISE Study)
|
||
Recruiting |
NCT04555369 -
The Value of ctDNA on Chemotherapy Efficacy for mCRC
|
N/A | |
Not yet recruiting |
NCT03688035 -
Potential of Circulating Tumor DNA to Assess the Tumor Response to Neoadjuvant Chemotherapy in Breast Cancer Patients
|
||
Recruiting |
NCT03737539 -
Dynamic Monitoring of ctDNA Methylation to Predict Relapse in Colorectal Cancer After Radical Resection (POSTCA)
|
||
Not yet recruiting |
NCT04511559 -
Methylation Analysis of Circulating Tumor DNA in Gastric Cancer
|
||
Recruiting |
NCT03748680 -
IMPROVE Intervention Trial Implementing Non-invasive Circulating Tumor DNA Analysis to Optimize the Operative and Postoperative Treatment for Patients With Colorectal Cancer
|
Phase 2 | |
Completed |
NCT02620527 -
Concordance Between ctDNA Assay and FoundationOne
|
||
Recruiting |
NCT05601505 -
Circulating Tumor DNA-guided Neoadjuvant Treatment Strategy for Locally Advanced Rectal Cancer
|
Phase 2 | |
Recruiting |
NCT05529615 -
Circulating Tumor DNA Guided Adjuvant Chemotherapy for Colon Cancer
|
N/A | |
Recruiting |
NCT05161585 -
Evaluation of Circulating Tumor DNA Guided Surveillance Strategy of Stage III Colorectal Cancer: an Open, Prospective, Randomized Controlled Cohort Study
|
N/A | |
Recruiting |
NCT05390112 -
Cohort Study of Patients With Hepatocellular Carcinoma and Circulating Tumor DNA Monitoring of Chemoembolization
|
||
Recruiting |
NCT05027828 -
CtDNA as a Novel Biomarker of Treatment Efficacy in Patients With Ovarian Cancer
|
||
Recruiting |
NCT06434896 -
Circulating Tumor DNA Based Adjuvant Chemotherapy in Stage II Colon Cancer Patients: the MEDOCC-CrEATE Trial
|
N/A | |
Recruiting |
NCT04966663 -
Using ctDNA to Determine Therapies for Lung Cancer
|
Phase 2 | |
Recruiting |
NCT05801263 -
ctDNA Methylation for Epithelial Ovarian Cancer
|
||
Recruiting |
NCT05801276 -
ctDNA Methylation for Detecting Ovarian Cancer
|
||
Active, not recruiting |
NCT04276337 -
Genetic Characteristics of HER2 Positive Breast Cancer With Neoadjuvant TCHP Chemotherapy
|
||
Recruiting |
NCT05969938 -
Predicting the Efficacy and Prognosis of Rectal Cancer Patients Based on ctDNA-MRD Technology
|
||
Completed |
NCT04456972 -
Reliability and Interest of Circulating Tumor DNA in Endometrial Cancers.
|
N/A |